What is William Blair's Estimate for TWST Q2 Earnings?

Twist Bioscience Co. (NASDAQ:TWST - Free Report) - Research analysts at William Blair issued their Q2 2026 earnings estimates for shares of Twist Bioscience in a report issued on Tuesday, February 4th. William Blair analyst M. Larew anticipates that the company will post earnings per share of ($0.41) for the quarter. The consensus estimate for Twist Bioscience's current full-year earnings is ($2.12) per share.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.09. The firm had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. Twist Bioscience's revenue was up 24.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.75) EPS.

Other research analysts have also issued reports about the company. Barclays decreased their target price on Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating for the company in a report on Tuesday, November 19th. Leerink Partners lifted their price target on Twist Bioscience from $45.00 to $48.00 and gave the stock a "market perform" rating in a report on Thursday, October 17th. Robert W. Baird increased their price objective on Twist Bioscience from $48.00 to $54.00 and gave the company an "outperform" rating in a report on Tuesday. Wolfe Research began coverage on Twist Bioscience in a research note on Friday, December 13th. They set an "outperform" rating and a $60.00 target price for the company. Finally, JPMorgan Chase & Co. increased their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research note on Tuesday. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $53.80.

Twist Bioscience Trading Down 2.6 %

TWST traded down $1.40 during mid-day trading on Wednesday, hitting $52.30. 883,044 shares of the stock were exchanged, compared to its average volume of 786,851. The firm's fifty day moving average is $48.84 and its two-hundred day moving average is $46.32. Twist Bioscience has a 1-year low of $27.41 and a 1-year high of $60.90. The company has a market cap of $3.12 billion, a PE ratio of -15.47 and a beta of 1.87. The company has a current ratio of 4.96, a quick ratio of 4.54 and a debt-to-equity ratio of 0.03.

Institutional Trading of Twist Bioscience

Several large investors have recently bought and sold shares of TWST. Arizona State Retirement System boosted its stake in shares of Twist Bioscience by 1.3% during the 4th quarter. Arizona State Retirement System now owns 16,985 shares of the company's stock worth $789,000 after purchasing an additional 219 shares during the last quarter. Van ECK Associates Corp boosted its holdings in Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after purchasing an additional 267 shares during the last quarter. Signaturefd LLC increased its position in shares of Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after purchasing an additional 306 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Twist Bioscience by 2.3% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company's stock valued at $734,000 after purchasing an additional 363 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock worth $98,000 after purchasing an additional 381 shares during the last quarter.

Insider Buying and Selling

In other Twist Bioscience news, COO Patrick John Finn sold 10,340 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $48.00, for a total value of $496,320.00. Following the completion of the transaction, the chief operating officer now directly owns 221,061 shares of the company's stock, valued at approximately $10,610,928. This trade represents a 4.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Emily M. Leproust sold 5,200 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total value of $256,620.00. Following the completion of the transaction, the chief executive officer now directly owns 667,318 shares of the company's stock, valued at $32,932,143.30. The trade was a 0.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 59,002 shares of company stock valued at $2,851,681 over the last ninety days. Corporate insiders own 3.01% of the company's stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.